Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy
MW McCarthy - Clinical Pharmacokinetics, 2020 - Springer
Abstract On 16 July, 2019, the US Food and Drug Administration approved imipenem–
cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract …
cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract …
Design, synthesis, and evaluation of novel pleuromutilin aryl acrylate derivatives as promising broad-spectrum antibiotics especially for combatting multi-drug resistant …
M Li, J Li, J Li, J Zhang, Y Zhao, W Li, Y Zhang… - European Journal of …, 2023 - Elsevier
The emergence of drug-resistant strains presents a grave challenge for traditional
antibiotics, underscoring the exigency of exploring novel antibacterial drugs. To address …
antibiotics, underscoring the exigency of exploring novel antibacterial drugs. To address …
Pharmacokinetic/pharmacodynamic based breakpoints of polymyxin B for bloodstream infections caused by multidrug-resistant gram-negative pathogens
X Bian, X Liu, F Hu, M Feng, Y Chen… - Frontiers in …, 2022 - frontiersin.org
The latest PK/PD findings have demonstrated negligible efficacy of intravenous polymyxins
against pulmonary infections. We investigated pharmacokinetic/pharmacodynamic (PK/PD) …
against pulmonary infections. We investigated pharmacokinetic/pharmacodynamic (PK/PD) …
[HTML][HTML] Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit
Despite long-term research achievements, the development of cell therapy (CT) products
remains challenging. This is because the risks experienced by the subject and therapeutic …
remains challenging. This is because the risks experienced by the subject and therapeutic …
Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation
YA Surovoy, MA Burkin, IA Galvidis… - Journal of …, 2022 - academic.oup.com
Objectives To describe polymyxin B pharmacokinetics in patients receiving veno-venous
extracorporeal membrane oxygenation (ECMO) in comparison with critically ill patients …
extracorporeal membrane oxygenation (ECMO) in comparison with critically ill patients …
Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation
H Wickremasinghe, HH Yu, MAK Azad, J Zhao… - Antibiotics, 2021 - mdpi.com
The emergence of antibiotic resistance has severely impaired the treatment of chronic
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Since …
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Since …
Kolistīna lietošanas prakse un nefrotoksicitāte kritiski slimiem pacientiem ar karbapenēmu rezistentu gramnegatīvo baktēriju infekciju. Promocijas darbs
A Krūmiņa - 2023 - dspace.rsu.lv
Ievads. Kolistīns ir polimiksīnu grupas antibakteriāls līdzeklis, kas netika lietots sistēmisku
infekciju ārstēšanai daudzus gadus neirotoksicitātes un nefrotoksicitātes riska dēļ …
infekciju ārstēšanai daudzus gadus neirotoksicitātes un nefrotoksicitātes riska dēļ …
Establishing a Cell-Based Assay to Target Hyperactive Spleen Tyrosine Kinase for High-Throughput Drug Screen
SWS Chau - 2022 - search.proquest.com
Recently, five gain-of-function variants in Spleen Tyrosine Kinase (SYK) were identified in
patients with immune dysregulation and systemic inflammation. SYK is a cytoplasmic, non …
patients with immune dysregulation and systemic inflammation. SYK is a cytoplasmic, non …
[PDF][PDF] Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm …
H Wickremasinghe, HH Yu, MAK Azad, J Zhao… - 2021 - minerva-access.unimelb.edu.au
The emergence of antibiotic resistance has severely impaired the treatment of chronic
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Since …
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Since …
Synergy and Antagonism: The Criteria of the Formulation
J Bueno, J Bueno - Preclinical Evaluation of Antimicrobial Nanodrugs, 2020 - Springer
The pharmaceutical formulation is the process by which the active molecule is combined to
develop a final drug. Currently, in antimicrobial therapy, it is considered that the modulation …
develop a final drug. Currently, in antimicrobial therapy, it is considered that the modulation …